BR112013003682A2 - métodos para tratar doenças neurodegenerativas - Google Patents

métodos para tratar doenças neurodegenerativas

Info

Publication number
BR112013003682A2
BR112013003682A2 BR112013003682A BR112013003682A BR112013003682A2 BR 112013003682 A2 BR112013003682 A2 BR 112013003682A2 BR 112013003682 A BR112013003682 A BR 112013003682A BR 112013003682 A BR112013003682 A BR 112013003682A BR 112013003682 A2 BR112013003682 A2 BR 112013003682A2
Authority
BR
Brazil
Prior art keywords
isomers
methods
neurodegenerative diseases
geranylgeranyl acetone
increasing
Prior art date
Application number
BR112013003682A
Other languages
English (en)
Inventor
Ankush B Argade
Ben A Barres
Hiroaki Serizawa
Naoki Nakayama
Original Assignee
Coyote Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coyote Pharmaceuticals Inc filed Critical Coyote Pharmaceuticals Inc
Publication of BR112013003682A2 publication Critical patent/BR112013003682A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/203—Unsaturated compounds containing keto groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/15—Unsaturated ethers containing only non-aromatic carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/303—Compounds having groups having acetal carbon atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C07C45/676—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton by elimination of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

métodos para tratar doenças neurodegenerativas. a presente invenção refere-se aos isômeros 5-cis e 5-trans de geranilgeranil acetona, prefencialmente os isômeros sintéticos referidos, e composições farmacêuticas contendo os isômeros referidos. outros aspectos desta invenção se referem ao uso de geranilgeranil acetona e seus isômeros em métodos para inibição de morte neural, para aumentar a atividade neural, e para aumentar o crescimento de axônios e a viabilidade celular. geranilgeranil acetona é um fármaco antiúlcera conhecido usado comercialmente e em situações clínicas. além disso, foi demonstrado que a gga exerce efeitos citoprotetores sobre uma variedade de órgãos, tais como os olhos, o cérebro, eo coração.
BR112013003682A 2010-09-01 2011-08-31 métodos para tratar doenças neurodegenerativas BR112013003682A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37931610P 2010-09-01 2010-09-01
US201161510002P 2011-07-20 2011-07-20
PCT/US2011/050071 WO2012031028A2 (en) 2010-09-01 2011-08-31 Methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
BR112013003682A2 true BR112013003682A2 (pt) 2016-09-06

Family

ID=45773508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003682A BR112013003682A2 (pt) 2010-09-01 2011-08-31 métodos para tratar doenças neurodegenerativas

Country Status (11)

Country Link
US (1) US20120172453A1 (pt)
EP (1) EP2611765A4 (pt)
JP (1) JP2013540720A (pt)
KR (1) KR20130109103A (pt)
CN (1) CN103052619A (pt)
AU (1) AU2011295920A1 (pt)
BR (1) BR112013003682A2 (pt)
CA (1) CA2806238A1 (pt)
MX (1) MX2013001236A (pt)
RU (1) RU2013104184A (pt)
WO (1) WO2012031028A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2763949A4 (en) * 2011-10-04 2015-06-03 Coyote Pharmaceuticals Inc GERANYLGÉRANYLACETONE DERIVATIVES
CN104136018A (zh) * 2012-02-27 2014-11-05 日本乐敦制药株式会社 包含香叶基香叶基丙酮的眼科用组合物
IN2014MN01552A (pt) 2012-02-27 2015-05-08 Rohto Pharma
US20140171516A1 (en) * 2012-02-29 2014-06-19 Coyote Pharmaceuticals, Inc. Geranylgeranylacetone formulations
US9045403B2 (en) 2012-02-29 2015-06-02 Coyote Pharmaceuticals, Inc. Geranyl geranyl acetone (GGA) derivatives and compositions thereof
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof
WO2014107686A1 (en) * 2013-01-07 2014-07-10 Coyote Pharmaceuticals, Inc. Methods for treating neuron damage
WO2014123977A1 (en) * 2013-02-06 2014-08-14 Rohto Usa, Inc. Geranylgeranylacetone formulations
WO2014151697A1 (en) * 2013-03-15 2014-09-25 Coyote Pharmaceuticals, Inc. Therapeutic uses for geranylgeranyl acetone and derivatives thereof
WO2014151719A1 (en) * 2013-03-15 2014-09-25 Coyote Pharmaceuticals, Inc. Sublingual formulations including geranylgeranylacetone and geranylgeranylacetone derivatives
WO2014163643A1 (en) * 2013-04-04 2014-10-09 Coyote Pharmaceuticals, Inc. Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
WO2015006614A2 (en) * 2013-07-11 2015-01-15 Coyote Pharmaceuticals, Inc. Gga derivatives
WO2015029925A1 (ja) * 2013-08-26 2015-03-05 ロート製薬株式会社 網膜疾患の予防、改善、又は治療剤
WO2015038680A1 (en) * 2013-09-11 2015-03-19 Coyote Pharmaceuticals, Inc. Drug conjugates of gga and gga derivatives
CN104447256A (zh) * 2014-11-13 2015-03-25 岳阳新华达制药有限公司 替普瑞酮中间体(5e,9e)-金合欢丙酮的制备方法
WO2016085954A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Geranygeranylacetone and analogs thereof and phenoxyalkylcarboxlic acids for treating fibrosis
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
KR20210040945A (ko) * 2018-06-21 2021-04-14 유마니티 테라퓨틱스, 인크. 신경장애의 치료 및 예방을 위한 조성물 및 방법
CN114031491B (zh) * 2021-11-26 2023-10-24 安徽先和医药研究有限公司 一种全反式替普瑞酮的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192073A (ja) * 1992-12-24 1994-07-12 Eisai Co Ltd 細胞分化誘導剤
EP1001987B1 (en) * 1997-08-01 2010-12-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
JP4632480B2 (ja) * 2000-05-16 2011-02-16 レドックス・バイオサイエンス株式会社 チオレドキシン誘導物質
US20040249219A1 (en) * 2000-07-05 2004-12-09 Saucy Gabriel G. Method of making teprenone
US20060135623A1 (en) * 2004-05-21 2006-06-22 Cutler Richard G Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs
WO2010042841A1 (en) * 2008-10-09 2010-04-15 University Of North Texas Health Science Center Combination therapies for the treatment of degenerative inflammatory conditions of the nervous system

Also Published As

Publication number Publication date
CA2806238A1 (en) 2012-03-08
WO2012031028A3 (en) 2012-07-05
EP2611765A2 (en) 2013-07-10
KR20130109103A (ko) 2013-10-07
WO2012031028A2 (en) 2012-03-08
US20120172453A1 (en) 2012-07-05
EP2611765A4 (en) 2014-06-11
CN103052619A (zh) 2013-04-17
RU2013104184A (ru) 2014-10-10
AU2011295920A1 (en) 2013-01-24
JP2013540720A (ja) 2013-11-07
MX2013001236A (es) 2013-05-01

Similar Documents

Publication Publication Date Title
BR112013003682A2 (pt) métodos para tratar doenças neurodegenerativas
CO2017011851A2 (es) Compuestos novedosos
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
BR112019022512A2 (pt) Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats
BR112015011158A2 (pt) triazolopirazina
BR112014021634A8 (pt) inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula
BR112013020041A2 (pt) compostos e métodos para a modulação de quinases, e indicações para os mesmos
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
PE20151375A1 (es) Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112015011298A2 (pt) inibidores de cotransportador 1 de glicose de sódio
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
UY32582A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
GT201400064A (es) Derivados de 8-carbamoil-2-(2,3- pirid-6-ilo di sustituido) -1,2,3,4- tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
BR112013000107A2 (pt) aminopirazoloquinazolinas
CU20120013A7 (es) Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
BR112016015235A2 (pt) Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
CR20120110A (es) Compuestos heterocíclicos y usos de los mismos
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
BR112012006010A2 (pt) composto de glicina
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112014003704A2 (pt) moduladores ror gama

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]